Evidence map›Paper›PMID 34359806›Full record

ArticleCancers2021

Evaluation of Colon-Specific Plasma Nanovesicles as New Markers of Colorectal Cancer.

Inga Nazarova, Maria Slyusarenko, Elena Sidina, Nadezhda Nikiforova, Vladislav Semiglazov, Tatiana Semiglazova, Achim Aigner, Evgeny Rybakov, Anastasia Malek

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Inga NazarovaSub-Cellular Technology Lab., N.N. Petrov National Medical Center of Oncology, Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, 197758 St. Petersburg, Russia.ORCID 0000-0002-6812-3088
Maria SlyusarenkoSub-Cellular Technology Lab., N.N. Petrov National Medical Center of Oncology, Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, 197758 St. Petersburg, Russia.ORCID 0000-0002-3677-1558
Elena SidinaSub-Cellular Technology Lab., N.N. Petrov National Medical Center of Oncology, Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, 197758 St. Petersburg, Russia.
Nadezhda NikiforovaSub-Cellular Technology Lab., N.N. Petrov National Medical Center of Oncology, Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, 197758 St. Petersburg, Russia.ORCID 0000-0001-7464-4237
Vladislav SemiglazovSub-Cellular Technology Lab., N.N. Petrov National Medical Center of Oncology, Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, 197758 St. Petersburg, Russia.
Tatiana SemiglazovaSub-Cellular Technology Lab., N.N. Petrov National Medical Center of Oncology, Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, 197758 St. Petersburg, Russia.
Achim AignerClinical Pharmacology, Rudolf-Boehm-Institute for Pharmacology and Toxicology, Faculty of Medicine, University of Leipzig, 04107 Leipzig, Germany.ORCID 0000-0002-2778-6256
Evgeny RybakovRyzhikh National Medical Research Center of Coloproctology, Department of Oncoproctology, 123423 Moscow, Russia.
Anastasia MalekSub-Cellular Technology Lab., N.N. Petrov National Medical Center of Oncology, Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, 197758 St. Petersburg, Russia.ORCID 0000-0001-5334-7292
First Pavlov State Medical University of St. Petersburg · RULeipzig University · DEState Scientific Center of Coloproctology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDeveloping new and efficient approaches for the early diagnosis of colorectal cancer (CRC) is an important issue. Circulating extracellular nanovesicles (ENVs) present a promising class of cancer markers. Cells of well-differentiated adenocarcinomas retain the molecular characteristics of colon epithelial cells, and the ENVs secreted by these cells may have colon-specific surface markers. We hypothesize that an increase in the number of ENVs carrying colon-specific markers could serve as a diagnostic criterion for colorectal cancer. EXPERIMENTAL

designPotential colon-specific markers were selected based on tissue-specific expression profile and cell surface membrane localization data. Plasma was collected from CRC patients (n = 48) and healthy donors (n = 50). The total population of ENVs was isolated with a two-phase polymer system. ENVs derived from colon epithelium cells were isolated using immune-beads with antibodies to colon-specific markers prior to labelling with antibodies against exosomal tetraspanins (CD63 and CD9) and quantification by flow cytometry.

resultsThe number of ENVs positive for single colon cancer markers was found to be significantly higher in the plasma of CRC patients compared with healthy donors. The efficacy of detection depends on the method of ENV labelling. The diagnostic efficacy was estimated by ROC analysis (the AUC varied between 0.71 and 0.79). The multiplexed isolation of colon-derived ENVs using immune-beads decorated with antibodies against five markers allowed for a further increase in the diagnostic potency of the method (AUC = 0.82).

conclusionsENVs derived from colon epithelium may serve as markers of differentiated CRC (adenocarcinomas). The composition of ligands used for capturing colon-derived ENVs and their method of labelling are critical for the efficacy of this proposed diagnostic approach.

Indexed as

colon cancerepithelial differentiationextracellular nanovesicles

Identifiers

PMID34359806
PMCPMC8345452
OpenAlexW3188468941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.